Pyxis Oncology (PYXS) Current Assets (2020 - 2026)
Pyxis Oncology (PYXS) posted quarterly Current Assets of $72.1 million for Q4 2025, down 45.56% year-over-year from $132.4 million in Q4 2024, and down 13.2% quarter-over-quarter from $83.1 million in Q3 2025.
Pyxis Oncology (PYXS) Current Assets (2020 - 2026) Analysis & Trends
Pyxis Oncology (PYXS) has reported Current Assets for 6 consecutive years, with $72.1 million the latest figure, recorded in Q4 2025.
- In Q4 2025, Current Assets fell 45.56% year-over-year to $72.1 million; the TTM figure through Dec 2025 stood at $72.1 million (down 45.56% YoY), while the FY2025 annual figure was $72.1 million, down 45.56% from the prior year.
- Current Assets slipped to $72.1 million in Q4 2025 per PYXS's latest filing, from $83.1 million in the prior quarter.
- Across five years, Current Assets topped out at $278.7 million in Q4 2021 and bottomed at $72.1 million in Q4 2025.
- Historically, Current Assets has averaged $157.3 million across 5 years, with a median of $149.1 million in 2023.
- Annual changes were most pronounced in 2021 — Current Assets soared 3339.13% — and 2025, when it tumbled 45.56%.
- Pyxis Oncology's Current Assets stood at $278.7 million in 2021, then slumped by 33.04% to $186.6 million in 2022, then slumped by 33.23% to $124.6 million in 2023, then climbed by 6.29% to $132.4 million in 2024, then sank by 45.56% to $72.1 million in 2025.
- Business Quant data shows PYXS's Current Assets at $72.1 million in Q4 2025, $83.1 million in Q3 2025, and $100.0 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 12.54 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 18.45 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 8.07 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.82 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 7.22 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 4.62 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 1.63 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 1.76 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 18.80 Bn |
| 10 | Pyxis Oncology | 199.01 Mn | 166.02 Mn | - | 36.73 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 36.73 Mn |
| Dec 31, 2025 | 72.11 Mn |
| Sep 30, 2025 | 83.07 Mn |
| Jun 30, 2025 | 99.96 Mn |
| Mar 31, 2025 | 111.87 Mn |
| Dec 31, 2024 | 132.44 Mn |
| Sep 30, 2024 | 148.87 Mn |
| Jun 30, 2024 | 161.04 Mn |
| Mar 31, 2024 | 172.38 Mn |
| Dec 31, 2023 | 124.60 Mn |
| Sep 30, 2023 | 139.09 Mn |
| Jun 30, 2023 | 149.30 Mn |
| Mar 31, 2023 | 156.18 Mn |
| Dec 31, 2022 | 186.61 Mn |
| Sep 30, 2022 | 202.81 Mn |
| Jun 30, 2022 | 226.60 Mn |
| Mar 31, 2022 | 251.26 Mn |
| Dec 31, 2021 | 278.67 Mn |
| Sep 30, 2021 | 134.34 Mn |
| Dec 31, 2020 | 8.10 Mn |